The Real Downside of GLP-1 Drugs (And Why Scott's Still Bullish) | Office Hours

The Prof G Pod
The Prof G PodApr 17, 2026

Why It Matters

GLP‑1 drugs could dramatically lower obesity‑related healthcare costs while reshaping treatment paradigms, making their responsible adoption a critical economic and public‑health priority.

Key Takeaways

  • GLP‑1 drugs cause 25‑39% lean‑mass loss, similar to calorie restriction.
  • Benefits include weight loss, cardiovascular, liver, kidney, and addiction improvements.
  • Projected US users could reach 25 million by 2030, reshaping healthcare costs.
  • Scott argues GLP‑1 impact may surpass AI’s economic significance.
  • Mitigating muscle loss requires resistance training, protein intake, and monitoring.

Summary

In this Office Hours episode, Scott discusses the growing prominence of GLP‑1 drugs, addressing both their impressive health benefits and the concerns surrounding lean‑mass loss. He notes that studies show 25‑39% of total weight loss on GLP‑1s is lean tissue, a proportion comparable to traditional calorie‑restriction diets, and emphasizes that the loss is largely a function of rapid weight reduction rather than a unique drug effect.

Scott highlights the drugs' broader therapeutic impact: beyond obesity, they reduce cardiovascular events, fatty liver disease, sleep apnea, kidney disease, and even show promise in treating addiction and delaying early‑onset dementia. Adoption is accelerating, with JP Morgan estimating ten million American users in 2025 and a projection of 25 million by 2030, suggesting a potential shift in national healthcare expenditures.

He argues that the societal upside could dwarf other tech trends, even AI, by cutting obesity‑related costs that account for a sizable share of the U.S. budget deficit. To mitigate muscle loss, Scott recommends resistance training three to five times weekly, protein intake of 1.6‑2.3 g per kilogram of fat‑free mass, and routine monitoring, positioning the regimen as a manageable trade‑off.

The episode also touches on personal finance and caregiving dilemmas, underscoring that financial resources can ease child‑raising challenges and that strategic planning—whether for health interventions or family support—remains essential for long‑term stability.

Original Description

Scott Galloway addresses concerns about muscle loss on GLP-1 drugs and explains why he's still bullish, unpacks the financial and emotional strain of supporting aging family members, and makes the case for putting the pedal down on your career before it's too late.
Want to be featured in a future episode? Send a voice recording to officehours@profgmedia.com, or drop your question in the r/ScottGalloway subreddit: https://bit.ly/3PGtUfm
Timestamps:
00:00 - In This Episode
01:01 - Trade-offs of GLP-1s
07:41 - Caring for Aging Parents While Raising Kids
12:29 - Working Moms, Ambition, and Family Life
Music: https://www.davidcuttermusic.com / @dcuttermusic
Subscribe to The Prof G Pod on Spotify
Want more Prof G? Check out everything we're up to at
#business #news #tech #finance #masculinity #profg #scottgalloway #advice #ProfGOfficeHours #glp1 #family #podcast #worklifebalance #parenting #highlights #jobmarket #podcast #professor

Comments

Want to join the conversation?

Loading comments...